Table 1.

Kaplan–Meier survival curves for all groups of mice with 4T1 tumors were analyzed for significance against vehicle-treated mice, and the combination therapies were additionally analyzed against the enzyme prodrug therapy

Synergism assessment factors
MedianP vs.P vs.Day of treatment
survivalvehiclemCTH-ANXA5 & Sel026913
Vehicle14 days
Cyc23 days0.2739
Rap14 days0.7830
Sel18 days0.8813
mCTH-ANXA518 days0.5215
Cyc & Rap24 days0.13150.00−0.030.06−0.10−0.02
mCTH-ANXA5 & Sel26 days0.10050.000.120.070.060.04
mCTH-ANXA5 & Sel + Rap27 days0.0015a0.03030.00−0.230.100.060.20
mCTH-ANXA5 & Sel + Cyc28 days0.00790.05600.000.09−0.010.000.12
mCTH-ANXA5 & Sel + Cyc & Rap36 days0.0002a0.0014a0.00−0.030.070.150.19
  • NOTE: The quantification of the synergism assessment based on primary tumor growth inhibition using the Bliss independence model is summarized for percent tumor inhibition for the combination therapies. Values presented as a function of the day of treatment are a “synergism assessment factor” with positive values indicative of synergism (bold), calculated from experimental values for the individual constituents of the combination therapies, and compared with the experimentally determined values of the combination therapies (see Supplementary Data for additional information about the assessment of synergism).

  • Abbreviations: Cyc, cyclophosphamide; Rap, rapamycin; Sel, selenomethionine.

  • aLog-rank–determined P values are presented and significance is indicated (P < 0.005).